CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $16,043,610
- in 4 filings, $16.0M under 10b5-1 plans
Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −23,465 | $81.75 | $1.9M | 4,365 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −3,865 | $82.66 | $319K | 500 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −200 | $83.38 | $17K | 300 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −300 | $85.53 | $26K | 0 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −16,182 | 63,818 | ||
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −17,500 | 42,500 | ||
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 50,000 | ||
| 2026-02-03 | Savitz Ryan EVP, CFO & CBO | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2026-02-03 | Randhawa Simrat EVP, Head of R&D | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2026-02-03 | Veness Adam M SVP, General Counsel and Sec. | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2026-02-03 | Garcia Marino CEO AND PRESIDENT | Grant or award · Stock Option (Right to Buy) | +355,000 | 355,000 | ||
| 2026-02-03 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2025-12-04 | Savitz Ryan CFO & CBO | Option exercise 10b5-1 | +20,000 | $8.44 | $169K | 20,000 |
| 2025-12-04 | Savitz Ryan CFO & CBO | Sale 10b5-1 | −20,000 | $45.18 | $904K | 0 |
| 2025-12-04 | Savitz Ryan CFO & CBO | Option exercise · Stock Option (Right to Buy) 10b5-1 | +20,000 | 84,766 | ||
| 2025-11-14 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +40,287 | $17.88 | $720K | 44,287 |
| 2025-11-14 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +37,494 | $21.77 | $816K | 81,781 |
| 2025-11-14 | Randhawa Simrat EVP, Head of R&D | Option exercise 10b5-1 | +31,250 | $22.07 | $690K | 113,031 |
| 2025-11-14 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −109,031 | $38.14 | $4.2M | 4,000 |
| 2025-11-14 | Randhawa Simrat EVP, Head of R&D | Option exercise · Stock Option (Right to Buy) 10b5-1 | −40,287 | 76,184 |
Page 9 of 24 · 470 trades